FDA Conducting Safety Review of Commonly Used Prostate Cancer Drugs

Gonadotropin-Releasing Hormone (GnRH) agonists, a class of medications primarily used to treat men with prostate cancer, have been associated with a small increased risk for diabetes, heart attack, stroke, and sudden death in men treated with one of the medications, according to a preliminary and ongoing analysis of several studies by the U.S. Food and Drug Administration.
Based on initial findings, FDA advises:

Health care professionals should be aware of these potential risks and carefully weigh the benefits and risks of GnRH agonists when determining a treatment for patients with prostate cancer.

Patients receiving a GnRH agonist should be monitored for the development of diabetes and cardiovascular disease.

Cardiovascular risk factors such as smoking and increases in blood pressure, cholesterol, blood sugar and weight should be managed according to current clinical practice.

Patients should not stop treatment with a GnRH agonist unless instructed to do so by a health care professional.

At this time, FDA has not made any conclusions about whether GnRH agonists cause an increase in the risk of diabetes and heart disease in patients receiving one of these medications to treat prostate cancer.

For more information, please visit: GnRH Agonists

open here to see the updated full-text:
FDA Conducting Safety Review of Commonly Used Prostate Cancer Drugs